Chinese biopharmaceutical company Akeso Inc (HK:9926) announced on Wednesday that it has completed patient enrolment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) assessing cadonilimab, a PD-1/CTLA-4 bispecific antibody independently developed by the company, as an adjuvant treatment for hepatocellular carcinoma (HCC) with high recurrence risk subsequent to curative resection or ablation.

In addition to this Phase III study, another Phase III trial investigating cadonilimab in combination with lenvatinib and transarterial chemoembolization (TACE) for the treatment of unresectable intermediate to advanced HCC is currently progressing on schedule.

The extensive exploration of combination therapies involving cadonilimab for HCC is expected to offer more effective treatment options for both early-stage and advanced HCC patients.

Akeso said that it will continue to advance cadonilimab clinical development for multiple malignant tumours, with the aim to provide more therapeutic options for patients worldwide.